Image

Efficacy and Safety of Aspirin in Patients With Chronic Coronary Syndromes Without Revascularization

Recruiting
20 years of age
Both
Phase 4

Powered by AI

Overview

The purpose of this study is to evaluate the efficacy and safety aspirin in patients with chronic coronary syndromes without revascularization.

Description

Aspirin for secondary prevention in the acute phase of acute coronary syndromes has been established. Although it is still disputable about the duration, there is also a consensus for antiplatelet therapy in patients after percutaneous coronary revascularization. On the other hand, several large randomized clinical trials (RCTs) have shown that aspirin treatment for primary prevention of cardiovascular events increases bleeding events and does not provide net clinical benefit.Patient with chronic coronary syndromes (CCS) but not eligible for revascularization do not belong to any of these categories and there is no evidence on the efficacy of aspirin in this population. Therefore, we designed a multicenter, randomized, open-label study to evaluate the efficacy and safety of aspirin in patients with CCS who are not eligible for revascularization.

Eligibility

Inclusion Criteria:

  • Patients with chronic coronary syndromes with ≧50% diameter stenosis in one or more major coronary vessels/major branches on coronary CT or coronary angiography but not eligible for coronary revascularization
  • Patients for whom consent can be obtained

Exclusion Criteria:

  • Patients with history of acute coronary syndromes (ACS)
  • Patients with history of percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG)
  • Patients with left main trunk stenosis (≥50%)
  • Patients for whom aspirin administration is mandatory
  • Patients undergoing antithrombotic therapy other than aspirin
  • Patients with atrial fibrillation
  • Patients with history of stroke within six months
  • Patients scheduled for major surgical procedures that will require aspirin discontinuation
  • Patients with contraindication of aspirin
  • Patients expected to have a prognosis of 1 year or less due to comorbidities
  • Women of child-bearing potential or women who have a positive pregnancy test at enrolment or randomization
  • Patients who are judged by attending physicians to be inappropriate to participate in this study

Study details

Stable Angina Pectoris, Coronary Artery Disease, Ischemic Heart Disease

NCT05347069

Takeshi Morimoto

27 January 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.